Alk-Abello A/S Patent applications |
Patent application number | Title | Published |
20140271722 | ALLERGEN DOSAGE FORM - The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided. | 09-18-2014 |
20140206027 | METHOD FOR QUANTIFICATION OF ALLERGENS - The invention relates to method for quantification of the absolute amount of allergen in an allergen sample comprising:
| 07-24-2014 |
20140127298 | MUCOSOMAL ALLERGEN-SPECIFIC IMMUNOTHERAPY WITH INITIAL DOSING AFTER START OF POLLEN SEASON - The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required. | 05-08-2014 |
20140010845 | SUPPRESSION OF A HYPERSENSITIVITY IMMUNE RESPONSE WITH UNRELATED ANTIGEN DERIVED FROM ALLERGEN SOURCE MATERIAL - The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen. | 01-09-2014 |
20130216582 | SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN - The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided. | 08-22-2013 |
20130195902 | RECOMBINANT ALLERGEN - Dander from the domestic cat ( | 08-01-2013 |
20130008818 | CONTAINER FOR A BLISTER PACKAGE - The present invention provides a container for storing a blister package and for managing medication with a pharmaceutical composition comprised in the blister package. The container comprises a housing which forms a compartment for the blister package, means for indicating towards a user an appropriate time of accessing the blister package, and means for detecting a users access to a blister package in the compartment. The blister package is moved into and out of the compartment by means of an ejection structure to which the blister package may be fixed. The ejection structure facilitates an enhanced handling of the blister package during insertion and removal of the blister package and facilitates a more accurate indication of a user's access to the blister package. | 01-10-2013 |
20120100164 | SUPPRESSION OF A HYPERSENSITIVITY IMMUNE RESPONSE WITH UNRELATED ANTIGEN DERIVED FROM ALLERGEN SOURCE MATERIAL - The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen. | 04-26-2012 |
20120100163 | SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN - The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided. | 04-26-2012 |
20120076825 | PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF - The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f). | 03-29-2012 |
20110236426 | PHARMACEUTICAL PRODUCT FOR UP-DOSING OF ALLERGY VACCINE - This invention relates to the use of a pharmaceutical product comprising allergen and optionally an adjuvant for fast up-dosing in connection with allergy vaccination wherein a reduced number of injections are used. The invention also relates to the pharmaceutical product as such. | 09-29-2011 |
20110142934 | MUCOSOMAL ALLERGEN-SPECIFIC IMMUNOTHERAPY WITH INITIAL DOSING AFTER START OF POLLEN SEASON - The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required. | 06-16-2011 |
20110104216 | PROCESSES FOR THE PREPARATION OF A BATCH OF AN ACTIVE PHARMACEUTICAL INGREDIENT, A CONTAINER COMPRISING CRYOGRANULES OF AN ALLERGEN PRODUCT, AND A CRYOGRANULE OF AN ALLERGEN PRODUCT - The present invention relates to processes for the preparation of a batch of an active pharmaceutical ingredient, e.g. an allergen product. The invention also relates to a container comprising cryogranules of a liquid composition of an allergen product, and to a cryogranule of an allergen product. The processes feature formation of cryogranules using a container having therein a cryogenic medium (e.g. liquid nitrogen) and storage of the cryogranules in the same container. The cryogranules obtained can be stored and handled without prior freeze-drying. | 05-05-2011 |
20110100030 | PROCESSES FOR THE PREPARATION OF A BATCH OF AN ACTIVE PHARMACEUTICAL INGREDIENT, A CONTAINER COMPRISING CRYOGRANULES OF AN ALLERGEN PRODUCT, AND A CRYOGRANULE OF AN ALLERGEN PRODUCT - The present invention relates to processes for the preparation of a batch of an active pharmaceutical ingredient, e.g. an allergen product. The invention also relates to a container comprising cryogranules of a liquid composition of an allergen product, and to a cryogranule of an allergen product. The processes feature formation of cryogranules using a container having therein a cryogenic medium (e.g. liquid nitrogen) and storage of the cryogranules in the same container. The cryogranules obtained can be stored and handled without prior freeze-drying. | 05-05-2011 |
20110052639 | ALLERGEN MUTANTS - Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are mutants of naturally occurring allergens. The overall α-carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof. | 03-03-2011 |
20100291155 | ALLERGY VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION - The present invention relates to an allergy vaccine composition for mucosal administration comprising a cysteine protease allergen in a reduced active state or in an oxidised inactive state, The inventions further relates to an adjuvant system for use in a vaccine for mucosal administration comprising a cysteine protease. | 11-18-2010 |
20100240098 | PROCESS FOR PRODUCING MATURE RECOMBINANT MITE GROUP I ALLERGEN - The present invention relates to a process for producing mature recombinant Mite Group I allergen comprising the steps of a) providing an allergen expression system in the form of a host cell selected from the group of yeasts containing a vector comprising cDNA encoding pro-allergen, b) cultivating the allergen expression system at a cultivation pH of between 5.5 and 7.5 for a cultivation period to express pro-allergen to obtain a cultivation mixture containing pro-allergen, c) adjusting the pH of the cultivation mixture to a maturation pH of between 3.5 and 5.0, d) maintaining the cultivation mixture at the maturation pH for a maturation period to convert the pro-allergen into mature allergen to obtain a product mixture, and e) subjecting the product mixture to a purification method to isolate mature allergen from the product mixture. | 09-23-2010 |
20100236973 | Container For a Blister Package - The present invention provides a container for storing a blister package and for managing medication with a pharmaceutical composition comprised in the blister package. The container comprises a housing which forms a compartment for the blister package, means for indicating towards a user an appropriate time of accessing the blister package, and means for detecting a users access to a blister package in the compartment. The blister package is moved into and out of the compartment by means of an ejection structure to which the blister package may be fixed. The ejection structure facilitates an enhanced handling of the blister package during insertion and removal of the blister package and facilitates a more accurate indication of a user's access to the blister package. | 09-23-2010 |
20100086569 | USE OF A FIRST HOUSE DUST MITE GROUP 2 ALLERGEN FOR TREATING ALLERGY TO A SECOND HOUSE DUST MITE GROUP 2 ALLERGEN - The present invention relates to the use of a Der f 2 allergen composition for the manufacture of a vaccine for preventing or treating allergy to Der p 2, as well as to the use of a Der p 2 allergen composition for the manufacture of a vaccine for treating allergy to Der f 2. | 04-08-2010 |
20100024048 | METHOD FOR MITE PRODUCTION - A method for culturing and producing mites, such as house dust mites, comprising culturing the mites in a suitable solid growth medium, under suitable conditions and for a suitable period of time in a suitable production room, characterized in that the mites are cultured in medium comprised within a closed bag. | 01-28-2010 |
20090258377 | Method of Measuring Enzymatic Activity of Adsorbed Allergenic Enzyme - The invention relates to a method of measuring the immunological activity of a vaccine preparation in the form of a mixture of one or more allergenic enzyme(s) and an oxygen-containing metal salt adjuvant, wherein the mixture comprises a liquid phase and a solid phase, and wherein at least a part of the allergenic enzyme(s) is adsorbed to the solid phase, the method comprising the steps of measuring the enzymatic activity of the mixture in an enzyme activity assay, and using the measurement obtained as an indication of the immunological activity of the vaccine preparation, or using the measurement obtained for quantifying the amount of allergenic enzyme. | 10-15-2009 |
20090197345 | METHOD FOR QUANTIFICATION OF ALLERGENS - The invention relates to method for quantification of the absolute amount of allergen in an allergen sample comprising: a) providing a known amount of one or more allergen calibration standard peptide(s) having a sequence of amino acids which is identical with, and optionally unique for, a sequence to be found in the allergen to be quantified and optionally labelling said allergen calibration standard peptide(s), b) degrading the allergen sample to obtain a mixture of peptides, and optionally labelling said peptides with one or more labelling agent(s), wherein at least the peptides in the degraded allergen sample or the calibration standard peptides are labelled, and if both the peptides in the degraded allergen sample and the allergen calibration standard peptide(s) are labelled, the labelling agent(s) used for labelling the allergen calibration standard peptide(s) are different from the labelling agent(s) used for labelling the peptides of the degraded allergen sample, c) quantifying the absolute amount of allergen by correlating the amount of the allergen calibration standard peptide(s) with the amount of the corresponding peptide(s) of the degraded allergen sample by mass analysis. | 08-06-2009 |
20090162403 | Process for producing an allergen extract - The present invention relates to a process for producing an allergen extract from a biological allergen source material comprising the steps of
| 06-25-2009 |
20090155351 | Solid Vaccine Formulation - The invention relates to a solid vaccine formulation adapted for mucosal administration comprising at least one antigen as active substance, wherein the formulation comprises a lyophilisate of a suspension comprising an oxygen-containing metal salt, the antigen(s) and one or more excipients selected from (i) saccharides, (ii) sugar alcohols, and (iii) amino acids or pharmaceutically acceptable salts thereof. | 06-18-2009 |
20090054625 | RECOMBINANT PROTEIN VARIANTS - The present invention relates to novel recombinant protein variants that are useful as immunotherapeutic components. Also the present invention relates to DNA sequences encoding said protein variants as well as compositions comprising said protein variants. | 02-26-2009 |
20080305505 | Method For Dissolution Testing of Pharmaceutical Products - The present invention relates to the field of dissolution measurement and, more particularly to methods for reproducible dissolution testing of pharmaceutical products such as allergen vaccines. | 12-11-2008 |
20080254058 | Pharmaceutical Composition Comprising a Bacterial Cell Displaying a Heterologous Proteinaceous Compound - The present invention pertains to a composition for the manufacture of a medicament comprising living or dead bacteria with controlled amounts of surface-coupled proteins or proteinaceous compounds and a method for the preparation of the composition. The bacterium provides a multivalent heterologous protein display vehicle that may be used in the manufacture of vaccines or medicaments for delivery via the mucosa. | 10-16-2008 |